Ad
ATNM - Actinium Pharmaceuticals Stock Trading
About | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.
Quote | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
| Last: | $5.32 |
|---|---|
| Change Percent: | -0.94% |
| Open: | $5.35 |
| Close: | $5.32 |
| High: | $5.44 |
| Low: | $5.19 |
| Volume: | 102,474 |
| Last Trade Date Time: | 12/08/2023 03:00:00 am |
News | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Acti...
-
2023-11-03 18:08:52 ET Summary Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing impro...
Message Board Posts | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
| Subject | By | Source | When |
|---|---|---|---|
| Been watching the share price and have to | timberwolf7 | investorshub | 04/11/2023 4:24:43 AM |
| whytestocks: $ATNM News Article - Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Po | whytestocks | investorshangout | 02/27/2023 1:05:46 PM |
| Results were definitely FDA approvable. Everyone is | Pharmboy46 | investorshub | 02/22/2023 6:38:21 PM |
| What's wrong? I don't understand! Down 5$ in | blukky | investorshub | 02/22/2023 6:26:34 PM |
| PUMP & DUMP | Lonewolf1 | investorshub | 02/21/2023 9:41:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Ad
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Acti...
-
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 PR Newswire NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announc...
-
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial PR Newswire - ...